• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Significance of an Abnormal Ankle-Brachial Index in Patients With Established Coronary Artery Disease With and Without Associated Diabetes Mellitus
In conclusion, in patients with stable CAD, an abnormal ABI confers an incremental risk of MACE in addition to DM and traditional CV risk factors.
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Subhash Banerjee, Ariel Vinas, Atif Mohammad, Omar Hadidi, Rahul Thomas, Karan Sarode, Avantika Banerjee, Puja Garg, Rick A. Weideman, Bertis B. Little, Emmanouil S. Brilakis Tags: Coronary Artery Disease Source Type: research

Influence of Cardiovascular and Non-Cardiovascular Comorbidities on Outcomes and Treatment Effect of Heart Rate Reduction with Ivabradine in Stable Heart Failure – (from the SHIFT trial)
Incidence of chronic heart failure (HF) increases with age and cardiovascular morbidity. Comorbidities increase hospitalization and mortality in HF, and non-cardiovascular comorbidities may lead to preventable hospitalizations. We studied the impact of comorbidities on mortality and morbidity in SHIFT, and investigated whether the impact of ivabradine was affected by comorbidities. We analyzed the SHIFT population, with moderate to severe HF and left ventricular dysfunction (in sinus rhythm with resting heart rate ≥70 bpm), according to comorbidity: chronic obstructive pulmonary disease, diabetes mellitus, anemia, stroke...
Source: The American Journal of Cardiology - October 5, 2015 Category: Cardiology Authors: Michael Böhm, Michele Robertson, Ian Ford, Jeffrey S. Borer, Michel Komajda, Ingrid Kindermann, Christoph Maack, Mitja Lainscak, Karl Swedberg, Luigi Tavazzi Source Type: research

Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With in Stable Heart Failure (from the SHIFT Trial)
Incidence of chronic heart failure (HF) increases with age and cardiovascular (CV) morbidity. Co-morbidities increase hospitalization and mortality in HF, and non-CV co-morbidities may lead to preventable hospitalizations. We studied the impact of co-morbidities on mortality and morbidity in Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial, and investigated whether the impact of ivabradine was affected by co-morbidities. We analyzed the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trialpopulation, with moderate-to-severe HF and left ventricular dysfunction (in sinus rhythm with h...
Source: The American Journal of Cardiology - October 5, 2015 Category: Cardiology Authors: Michael Böhm, Michele Robertson, Ian Ford, Jeffrey S. Borer, Michel Komajda, Ingrid Kindermann, Christoph Maack, Mitja Lainscak, Karl Swedberg, Luigi Tavazzi Tags: Heart Failure Source Type: research

Utility of Global Longitudinal Strain by Echocardiography to Detect Left Ventricular Dysfunction in Long-Term Adult Survivors of Childhood Lymphoma and Acute Lymphoblastic Leukemia
Measuring left ventricular (LV) global longitudinal strain (GLS) is recommended in screening of long-term cancer survivors for cardiotoxicity. However, there are limited data on GLS in this setting, in particular in survivors with apparently normal LV function without risk factors of impaired GLS. In the present study, we measured GLS in 191 adult survivors of childhood lymphoma or acute lymphoblastic leukemia, with normal LV ejection fraction (EF) and fractional shortening (FS), and without known hypertension, diabetes mellitus, myocardial infarction or stroke.
Source: The American Journal of Cardiology - May 13, 2016 Category: Cardiology Authors: Jon R. Christiansen, Richard Massey, Håvard Dalen, Adriani Kanellopoulos, Hanne Hamre, Sophie D. Fosså, Ellen Ruud, Cecilie E. Kiserud, Svend Aakhus Source Type: research

Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (From the Treating to New Targets (TNT) and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trials)
The goal of this analysis was to evaluate the ability of insulin resistance, identified by the presence of prediabetes mellitus (PreDM) combined with either an elevated triglyceride (TG>1.7mmol/L) or body mass index (BMI> 27.0 kg/m2), to identify increased risk of statin-associated type 2 diabetes mellitus (T2DM). Consequently, a retrospective analysis of data from non-diabetic individuals in the TNT and SPARCL randomized controlled trials was performed, subdividing participants into 4 experimental groups: 1) normal fasting glucose (NFG) and TG ≤ 1.7 mmol/L (42%); 2) NFG and TG> 1.7 mmol/L (22%); 3) PreDM and TG ≤ 1.7 ...
Source: The American Journal of Cardiology - August 11, 2016 Category: Cardiology Authors: Payal Kohli, Joshua W. Knowles, Ashish Sarraju, David D. Waters, Gerald Reaven Source Type: research

Comparison of the Incidence of Major Bleeding with Rivaroxaban Use among Nonvalvular Atrial Fibrillation Patients With versus Without Diabetes Mellitus
Diabetes mellitus (DM) is a common comorbidity in those with nonvalvular atrial fibrillation (NVAF). Most patients with DM and NVAF have a CHA2DS2-VASc score of ≥1 and should be considered for oral anticoagulation therapy for stroke prevention per treatment guidelines. The most important risk associated with anticoagulation is bleeding, which may be higher in those with NVAF plus DM. Our objective was to evaluate the incidence and characteristics of major bleeding (MB) in rivaroxaban users diagnosed with NVAF, further comparing those with DM versus those without DM, in a real-world clinical setting.
Source: The American Journal of Cardiology - December 7, 2016 Category: Cardiology Authors: W. Frank Peacock, Sally Tamayo, Nicholas Sicignano, Kathleen P. Hopf, Zhong Yuan, Manesh Patel Source Type: research

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing cardiovascular disease (CVD) - namely myocardial infarction, heart failure and stroke. Despite clear advances in the prevention and treatment of CVD, the impact of T2DM on CVD outcome remains high, and continues to escalate. Available evidence indicates that the risk of macrovascular complications increases with the severity of hyperglycemia, thus suggesting that the relation between metabolic disturbances and vascular damage is approximately linear.
Source: The American Journal of Cardiology - May 29, 2017 Category: Cardiology Authors: Francesco Paneni, Thomas F. L üscher Source Type: research

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A  Review of Clinical Trial Results Across Drug Classes
Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing cardiovascular disease (CVD) —namely myocardial infarction, heart failure, and stroke. Despite clear advances in the prevention and treatment of CVD, the impact of T2DM on CVD outcome remains high and continues to escalate. Available evidence indicates that the risk of macrovascular complications increases with the severity o f hyperglycemia, thus suggesting that the relation between metabolic disturbances and vascular damage is approximately linear.
Source: The American Journal of Cardiology - May 29, 2017 Category: Cardiology Authors: Francesco Paneni, Thomas F. L üscher Source Type: research

Myocardial Infarction Subtypes in Patients with Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (From the LEADER Trial)
Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI); however, data regarding MI subtypes in people with diabetes are limited. In the LEADER trial (N=9340), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (composite of CV death, non-fatal MI or non-fatal stroke) versus placebo in patients with type 2 DM and high CV risk. Liraglutide also reduced risk of first MI (292 events with liraglutide versus 339 with placebo). This post hoc analysis characterized MIs (first and recurrent) occurring in LEADER, by treatment arm and regarding incidence, outcome, subtype and troponin levels.
Source: The American Journal of Cardiology - March 15, 2018 Category: Cardiology Authors: Steven P. Marso, Michael A. Nauck, Tea Monk Fries, S øren Rasmussen, Marianne Bach Treppendahl, John B. Buse, LEADER Trial Investigators Source Type: research

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)
Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI); however, data regarding MI subtypes in people with diabetes are limited. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (n  = 9,340), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (composite of CV death, nonfatal MI, or nonfatal stroke) versus placebo in patients with type 2 DM and high CV risk. Liraglutide also reduced risk of first MI (292 events with liraglutide vs 339 wit h placebo).
Source: The American Journal of Cardiology - March 15, 2018 Category: Cardiology Authors: Steven P. Marso, Michael A. Nauck, Tea Monk Fries, S øren Rasmussen, Marianne Bach Treppendahl, John B. Buse, LEADER Publication Committee on behalf of the LEADER Trial Investigators Source Type: research

Lipid-Lowering Prescription Patterns in Patients with Diabetes Mellitus or Cardiovascular Disease
The purpose of this study is to describe lipid-lowering therapy (LLT) prescriptions and low-density lipoprotein cholesterol (LDL-C) monitoring in patients with diabetes mellitus (DM) with or without concomitant cardiovascular disease (CVD). Olmsted County, MN residents with a first-ever diagnosis of DM or CVD (ischemic stroke/transient ischemic attack, myocardial infarction, unstable angina pectoris, or revascularization procedure) between 2005 and 2012 were classified as having DM only, CVD only, or CVD  + DM.
Source: The American Journal of Cardiology - July 14, 2019 Category: Cardiology Authors: Alanna M. Chamberlain, Sarah S. Cohen, Jill M. Killian, Keri L. Monda, Susan A. Weston, Ted Okerson Source Type: research

Comparison of Long-Term Risk Adverse Outcomes In Patients with Atrial Fibrillation Having Ablation vs Antiarrhythmic Medications
The impact of atrial fibrillation (AF) catheter ablation vs. chronic antiarrhythmic therapy alone on clinical outcomes such as death and stroke remains unclear. We compared adverse outcomes for AF ablation versus chronic antiarrhythmic therapy in 1070 adults with AF treated between 2010 and 2014 in the Kaiser Permanente Northern California and Southern California healthcare delivery systems. Patients undergoing AF catheter ablation were matched to patients treated with only antiarrhythmic medications, based on age, gender, history of heart failure, history of coronary heart disease, history of hypertension, history of diab...
Source: The American Journal of Cardiology - November 18, 2019 Category: Cardiology Authors: James V. Freeman, Grace H. Tabada, Kristi Reynolds, Sue Hee Sung, Daniel E. Singer, Paul J. Wang, Taylor I. Liu, Nigel Gupta, Mark A. Hlatky, Alan S. Go Source Type: research

Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications
The impact of atrial fibrillation (AF) catheter ablation versus chronic antiarrhythmic therapy alone on clinical outcomes such as death and stroke remains unclear. We compared adverse outcomes for AF ablation versus chronic antiarrhythmic therapy in 1,070 adults with AF treated between 2010 and 2014 in the Kaiser Permanente Northern California and Southern California healthcare delivery systems. Patients who underwent AF catheter ablation were matched to patients treated with only antiarrhythmic medications, based on age, gender, history of heart failure, history of coronary heart disease, history of hypertension, history ...
Source: The American Journal of Cardiology - November 18, 2019 Category: Cardiology Authors: James V. Freeman, Grace H. Tabada, Kristi Reynolds, Sue Hee Sung, Daniel E. Singer, Paul J. Wang, Taylor I. Liu, Nigel Gupta, Mark A. Hlatky, Alan S. Go Source Type: research

Use of the Burden of Diabetes Mellitus Score for Cardiovascular Disease Risk Assessment
The prevalence of diabetes mellitus (DM) is rising drastically with> 400 million patients living with the disorder worldwide.1-3 DM is associated with severe complications including coronary artery disease (CAD), stroke, neuropathy, retinopathy, and nephropathy.2,4,5 Of these, cardiovascular (CV) disease is the most substantial cause of morbidity and mortality.6-9 Hemoglobin A1c (HbA1c) levels and duration of disease are 2 of the strongest predictors of poor CV outcomes including mortality.1,2,5,7,10,11 One study showed that early onset DM with> 10 years duration was equivalent to CAD itself.
Source: The American Journal of Cardiology - April 3, 2020 Category: Cardiology Authors: Peter D. Farjo, Nadia Barghouthi, Noor Chima, Anand Desai, Wei Fang, Jennifer Giordano, Christopher M. Bianco Source Type: research

Pages: 1  2  3  4